FOR IMMEDIATE RELEASE Covington, KY - Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain and solid tumors, announced today that it will feature one clinical poster presentation and three online publications at the [...]
FOR IMMEDIATE RELEASE Covington, KY April 16, 2018 - Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on rare brain tumors, announced today that the four abstracts submitted for presentation at the American Society of Clinical [...]
Bexion Pharmaceuticals is developing innovative cures for cancer.
Unlike any other potential drug known in development, BXQ-350 has an entirely new and novel mechanism of action.
In July 2016 Bexion received a “Study May Proceed” letter from the FDA, allowing Bexion to initiate the first clincial trial using BXQ-350 to dose patients with cancer (solid tumors and glioblastoma).
Information about the Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors trial can be found at https://www.clinicaltrials.gov/show/NCT02859857